Updated Jul 16, 2026 · Last SEC filing 2026-07-06
Allogene Therapeutics, Inc. (ALLO) has filed 9 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-06. 3 Form 8-K material event filings were reported by ALLO in the last 90 days. 1 Form 144 notices of proposed sale were filed for ALLO stock. InsiderAlpha tracks every ALLO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001737287 |
|---|
| Form 4 filings (90d) | 9 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-07-06 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Kazam Joshua A | Director | M — Option exercise | 47.7K | $0.00 | — | SEC | |
| Yoshiyama Annie | SVP, Finance | S — Open-market sale | 9.6K | $2.31 | $22K | SEC | |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | S — Open-market sale | 2.9K | $2.50 | $7K | SEC | |
| Chang David D | President and CEO | S — Open-market sale | 47.8K | $2.47 | $118K | SEC | |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | S — Open-market sale | 4.8K | $2.47 | $12K | SEC | |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | S — Open-market sale | 7.1K | $2.60 | $19K | SEC | |
| Douglas Earl Martin | SVP, General Counsel | S — Open-market sale | 22.9K | $1.76 | $40K | SEC | |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | S — Open-market sale | 7.5K | $1.73 | $13K | SEC | |
| Chang David D | President and CEO | S — Open-market sale | 95.3K | $1.80 | $171K | SEC | |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | S — Open-market sale | 24.0K | $1.76 | $42K | SEC | |
| Yoshiyama Annie | SVP, Finance | S — Open-market sale | 4.2K | $1.72 | $7K | SEC | |
| Roberts Zachary | EVP of R&D | S — Open-market sale | 35.7K | $1.77 | $63K | SEC | |
| Roberts Zachary | EVP of R&D | S — Open-market sale | 26.3K | $1.56 | $41K | SEC | |
| MESSEMER DEBORAH M. | Director | S — Open-market sale | 9.1K | $2.18 | $20K | SEC | |
| Humer Franz B | Director | S — Open-market sale | 9.2K | $2.16 | $20K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Allogene Therapeutics, Inc. (ALLO). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Kazam Joshua A | 3 | — |
| Roberts Zachary | 2 | — |
| MESSEMER DEBORAH M. | 1 | — |
| Humer Franz B | 1 | — |
| Yoshiyama Annie | 1 | $22K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ALLO insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ALLO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.